Compare Comcast Corporation (CMCSA) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comcast Corporation vs Incyte Corporation — how do they compare? Comcast Corporation trades at $25.46 (market cap $91.02B), while Incyte Corporation trades at $120.67 (market cap $24.54B). The key difference: Comcast Corporation is far larger — about 3.7× Incyte Corporation's market cap, and Comcast Corporation pays a 5.15% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| CMCSA | INCY | |
|---|---|---|
Market Cap | $91.02B | $24.54B |
Sector | Media | Health |
52-Week High | $32.50 | $129.93 |
52-Week Low | $21.92 | $81.61 |
Enterprise Value | $173.74B | $20.04B |
Dividend Yield | 5.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Comcast (CMCSA) trades at $25.35, up 0.6% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.04 versus $0.97 expected, driven by wireless growth and Peacock profitability. Recent news highlights expansion of high-speed internet services and strategic initiatives like the NBCUniversal spinoff. Fundamentals show robust cash flow generation, with 2025 operating cash flow at $33.64 billion, and attractive valuation metrics including a P/E of 8.22 and EV/EBITDA of 5.09.
The outlook for CMCSA is positive, supported by analyst consensus with a $27.78 price target and 55.74% buy ratings. Investment opportunities include the potential upside from the NBCUniversal separation and sustained dividend payments. Key risks involve competitive pressures in broadband, theme park volatility, and integration challenges from corporate restructuring. The stock offers value with solid fundamentals but faces execution risks in a dynamic media landscape.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
